METHODS: We report a 5-year-old patient with immediate recurrence of positive myeloperoxidase (MPO)-ANCA vasculitis after deceased donor kidney transplant and the novel use of eculizumab to salvage the graft.
RESULTS: Eculizumab and transition to ravulizumab has been successful in improving graft function and maintenance of disease remission after immediate MPO-ANCA vasculitis recurrence posttransplant.
CONCLUSIONS: Complement inhibitors may be used in addition to standard immunosuppression postkidney transplant in a pediatric patient with MPO-ANCA vasculitis recurrence without higher rates of infections.
方法:我们报告了一名5岁患者,在已死亡的供体肾脏移植后,髓过氧化物酶(MPO)-ANCA血管炎阳性立即复发,并新使用依库珠单抗挽救移植物。
结果:Eculizumab和过渡到ravulizumab在移植后MPO-ANCA血管炎立即复发后成功改善移植物功能和维持疾病缓解。
结论:对于MPO-ANCA血管炎复发且无较高感染率的儿科患者,除了标准的肾移植后免疫抑制外,还可以使用补体抑制剂。